Novant Health, an integrated network of physician clinics, outpatient facilities and hospitals in Virginia, North and South Carolina and Georgia, revealed on Monday the appointment of Ann Caulkins as its senior vice president as well as president of its Novant Health Foundation.
Based in Winston-Salem, North Carolina, Caulkins will design and implement plans for sustainable and integrated philanthropy across all its markets, increase the profile of the foundation within its communities, with focus on infants and children, cancer, heart and vascular, stroke and neuroscience as well as research and education.
Most recently, Caulkins has served as the president and publisher of The Charlotte Observer for 12 years.
Previously, Caulkins was the president and publisher of The State newspaper in Columbia, South Carolina, advertising director and senior vice president of sales and marketing at The Herald-Leader in Lexington, Kentucky as well as part of the Fort Worth Star-Telegram in Fort Worth, Texas at the start of her newspaper career.
Caulkins is currently a member of the boards of CrossRoads Charlotte, The Fletcher School and the Charlotte Mecklenburg Library Foundation, as well as a member of the Women's Impact Fund, International Women's Forum, Women Executives and the National Association of Corporate Directors.
Earlier, Caulkins was a member of the Charlotte Chamber of Commerce board, the Charlotte Regional Partnership board, the Queens University School of Communication Advisory Board, the Charlotte Country Day board, the University of North Carolina at Chapel Hill's School of Media and Journalism board of advisors, the Columbia Urban League board of directors and the South Carolina Palmetto Business Forum as well as board chair of the Levine Museum of the New South.
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
InSysBio agrees new collaborative project with BeOne Medicines
Physiomics secures new modelling contract with Numab Therapeutics
Mabwell reports first patient dosed with 7MW4911 in US trial
Atossa Therapeutics' founder and CEO named one of The Top 50 Healthcare Technology CEOs of 2025
Avacta secures FDA clearance for second pre|CISION oncology programme
Guardant Health and Merck enter multi-year oncology diagnostics collaboration
Akeso secures NMPA review acceptance for gumokimab in ankylosing spondylitis